ArticleBMC medical imaging2025
Evaluation of a fusion model combining deep learning models based on enhanced CT images with radiological and clinical features in distinguishing lipid-poor adrenal adenoma from metastatic lesions.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Differentiation of adrenal metastases and adenomas based on clinical characteristics, deep learning features, and radiomics features derived from ultrasound imaging.BMC medical imaging · 2026Article
- Machine Learning Approach for Differentiation of Pheochromocytoma from Adrenocortical Cancer and Non-Functioning Adrenal Adenomas.Life (Basel, Switzerland) · 2026Article
- AI-enabled precision evaluation of adrenal masses: radiomics, deep learning, and explainable imaging biomarkers.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo evaluate the diagnostic performance of a machine learning model combining deep learning models based on enhanced CT images with radiological and clinical features in differentiating lipid-poor adrenal adenomas from metastatic tumors, and to explain the model's prediction results through SHAP(Shapley Additive Explanations) analysis.
methodsA retrospective analysis was conducted on abdominal contrast-enhanced CT images and clinical data from 416 pathologically confirmed adrenal tumor patients at our hospital from July 2019 to December 2024. Patients were randomly divided into training and testing sets in a 7:3 ratio. Six convolutional neural network (CNN)-based deep learning models were employed, and the model with the highest diagnostic performance was selected based on the area under curve(AUC) of the ROC. Subsequently, multiple machine learning models incorporating clinical and radiological features were developed and evaluated using various indicators and AUC.The best-performing machine learning model was further analyzed using SHAP plots to enhance interpretability and quantify feature contributions.
resultsAll six deep learning models demonstrated excellent diagnostic performance, with AUC values exceeding 0.8, among which ResNet50 achieved the highest AUC. Among the 10 machine learning models incorporating clinical and imaging features, the extreme gradient boosting(XGBoost) model exhibited the best accuracy(ACC), sensitivity, and AUC, indicating superior diagnostic performance.SHAP analysis revealed contributions from ResNet50, RPW, age, and other key features in model predictions.
conclusionMachine learning models based on contrast-enhanced CT combined with clinical and imaging features exhibit outstanding diagnostic performance in differentiating lipid-poor adrenal adenomas from metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.